Scholar Rock Holding Co. (NASDAQ:SRRK) Director Sells $34,626.52 in Stock

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) Director Katie Peng sold 1,006 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $34.42, for a total value of $34,626.52. Following the completion of the sale, the director now directly owns 30,319 shares of the company's stock, valued at $1,043,579.98. This represents a 3.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Scholar Rock Price Performance

Shares of NASDAQ SRRK traded down $0.59 during trading on Friday, reaching $33.05. The company had a trading volume of 2,661,055 shares, compared to its average volume of 1,147,200. The business's 50 day moving average price is $38.74 and its 200-day moving average price is $32.20. Scholar Rock Holding Co. has a 52 week low of $6.76 and a 52 week high of $46.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The stock has a market cap of $3.13 billion, a PE ratio of -14.06 and a beta of 0.59.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Truist Financial raised their price target on shares of Scholar Rock from $36.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, November 25th. Wedbush reissued an "outperform" rating and set a $50.00 target price on shares of Scholar Rock in a research report on Monday, March 17th. Finally, HC Wainwright upped their price target on Scholar Rock from $40.00 to $50.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $40.86.

Remove Ads

Institutional Investors Weigh In On Scholar Rock

A number of institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in Scholar Rock by 51.8% in the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company's stock valued at $34,000 after buying an additional 269 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Scholar Rock by 1.0% in the third quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock valued at $310,000 after purchasing an additional 379 shares in the last quarter. Amalgamated Bank boosted its position in shares of Scholar Rock by 30.6% during the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company's stock worth $114,000 after buying an additional 620 shares during the period. Global Retirement Partners LLC grew its holdings in shares of Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after buying an additional 766 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after buying an additional 1,031 shares during the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.